Strata Skin Sciences (FRA:E2O) EBIT: €-4.02 Mil (TTM As of Dec. 2025)


FRA:E2O Strata Skin Sciences Inc FRA:E2O
38 GF Score
Price €3.76
GF Value €56.54
! 5 Warning Signs
View Full Analysis

What is Strata Skin Sciences EBIT?

Strata Skin Sciences FRA:E2O 38 EBIT is €-4.02 Mil as of Dec. 2025. GuruFocus rates FRA:E2O with a GF Score™ of 38/100 and a GF Value™ of €56.54. The stock has 5 warning signs investors should review.

Strata Skin Sciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was €0.47 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was €-4.02 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Strata Skin Sciences's annualized ROC % for the quarter that ended in Dec. 2025 was -8.80%. Strata Skin Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 21.70%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Strata Skin Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -44.27%.


Strata Skin Sciences  (FRA:E2O) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Strata Skin Sciences's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-2.212 * ( 1 - 0% )/( (20.684 + 29.602)/ 2 )
=-2.212/25.143
=-8.80 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Strata Skin Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1.892/( ( (8.999 + max(-4.853, 0)) + (8.441 + max(-2.967, 0)) )/ 2 )
=1.892/( ( 8.999 + 8.441 )/ 2 )
=1.892/8.72
=21.70 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.985 + 2.605 + 0.541) - (6.135 + 2.173 + 2.676)
=-4.853

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(3.519 + 2.403 + 0.643) - (5.978 + 1.92 + 1.634)
=-2.967

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Strata Skin Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-4.017/9.073
=-44.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Strata Skin Sciences EBIT Related Terms


Strata Skin Sciences EBIT Historical Data

* Premium members only.

The historical data trend for Strata Skin Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Strata Skin Sciences EBIT Chart

Strata Skin Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.09 -4.31 -8.51 -7.78 -3.66

Strata Skin Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.02 -1.80 -1.73 -0.96 0.47

FRA:E2O vs IRME, NUMD, WOK: EBIT Comparison

For the Medical Devices subindustry, Strata Skin Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strata Skin Sciences EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Strata Skin Sciences's EV-to-EBIT falls into.


FRA:E2O
38GF Score
Strata Skin Sciences Inc FRA:E2O
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Strata Skin Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-4.02 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-4.02 Mil mean?
Strata Skin Sciences (FRA:E2O) has a EBIT of €-4.02 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Strata Skin Sciences.
Is Strata Skin Sciences' EBIT too high?
Strata Skin Sciences' current EBIT is €-4.02 Mil. Overall, Strata Skin Sciences has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Strata Skin Sciences' EBIT compare to IRME and NUMD?
Strata Skin Sciences' EBIT of €-4.02 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Strata Skin Sciences. Strata Skin Sciences's current EBIT is €-4.02 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Skin Sciences stock overvalued right now?
Strata Skin Sciences (FRA:E2O) has a current EBIT of €-4.02 Mil. The stock's GF Value™ is €56.54, compared to a current price of €3.76 — trading 93.3% below its estimated fair value. The current EBIT is €-4.02 Mil. Strata Skin Sciences' overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Strata Skin Sciences (FRA:E2O), the current EBIT is €-4.02 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Strata Skin Sciences (FRA:E2O) Overvalued in 2026?

Based on GuruFocus' analysis, Strata Skin Sciences stock appears to be undervalued. The current stock price of €3.76 is trading 93.3% below its estimated GF Value™ of €56.54.

Key valuation signals for FRA:E2O:

  • EBIT: €-4.02 Mil
  • GF Value™: €56.54 vs. price of €3.76 (93.3% below fair value)
  • GF Score™: 38/100 with 5 warning signs

No single metric tells the full story. See the FRA:E2O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Strata Skin Sciences Business Description

Other Exchanges SSKN:USA
Address 5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo, and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures, which is the key revenue driver, and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
38GF Score

Get the complete analysis for FRA:E2O

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.76
Price
€56.54
GF Value